← Back to Screener
Oruka Therapeutics, Inc. Common Stock (ORKA)
Price$68.87
Favorite Metrics
Price vs S&P 500 (26W)172.67%
Price vs S&P 500 (4W)67.63%
Market Capitalization$3.48B
All Metrics
Book Value / Share (Quarterly)$9.69
P/TBV (Annual)2.93x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.81
Price vs S&P 500 (YTD)123.25%
Net Profit Margin (TTM)-26.27%
EPS (TTM)$-2.32
10-Day Avg Trading Volume1.40M
EPS Excl Extra (TTM)$-2.32
EPS (Annual)$-2.31
ROI (Annual)-22.34%
Net Profit Margin (5Y Avg)-9513.58%
Cash / Share (Quarterly)$6.92
ROA (Last FY)-21.58%
EBITD / Share (TTM)$-2.67
ROE (5Y Avg)-24.07%
Operating Margin (TTM)-40.31%
Cash Flow / Share (Annual)$-1.81
P/B Ratio7.37x
P/B Ratio (Quarterly)3.11x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)73.26x
Net Interest Coverage (TTM)-69.05x
ROA (TTM)-24.34%
EPS Incl Extra (Annual)$-2.31
Current Ratio (Annual)22.37x
Quick Ratio (Quarterly)21.92x
3-Month Avg Trading Volume0.69M
52-Week Price Return700.46%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)74.26x
Asset Turnover (Annual)0.39x
52-Week High$70.14
Operating Margin (5Y Avg)-9138.63%
EPS Excl Extra (Annual)$-2.31
CapEx CAGR (5Y)59.89%
26-Week Price Return181.42%
Quick Ratio (Annual)21.92x
13-Week Price Return115.38%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.37x
Enterprise Value$3,432.943
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)14.63%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-26.25%
Cash / Share (Annual)$6.92
3-Month Return Std Dev75.43%
Net Income / Employee (TTM)$-2
ROE (Last FY)-22.34%
Net Interest Coverage (Annual)-29.41x
EPS Basic Excl Extra (Annual)$-2.31
Receivables Turnover (TTM)10.19x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.32
Receivables Turnover (Annual)10.19x
ROI (TTM)-25.30%
P/S Ratio (TTM)74.26x
Pretax Margin (5Y Avg)-9092.39%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)665.37%
Year-to-Date Return127.38%
5-Day Price Return12.28%
EPS Normalized (Annual)$-2.31
ROA (5Y Avg)-23.01%
Net Profit Margin (Annual)-26.25%
Month-to-Date Return40.51%
EBITD / Share (Annual)$-2.67
Operating Margin (Annual)-40.31%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-24.07%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-2.32
P/TBV (Quarterly)2.00x
P/B Ratio (Annual)3.11x
Pretax Margin (TTM)-26.27%
Book Value / Share (Annual)$9.69
Price vs S&P 500 (13W)112.51%
Beta-0.28x
Revenue / Share (TTM)$0.00
ROE (TTM)-25.30%
52-Week Low$8.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.42
4.40
4.40
4.40
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. Common Stock | 74.26x | — | — | — | $68.87 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibodies for psoriasis and inflammatory diseases. Its lead programs—ORKA-001 and ORKA-002—target distinct inflammatory pathways (IL-23p19 and IL-17A/F) using high-affinity antibodies with extended half-lives to reduce dosing frequency. Both programs address psoriasis, with ORKA-002 also designed for psoriatic arthritis and related conditions.